{"nctId":"NCT00972283","briefTitle":"Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes","startDateStruct":{"date":"2009-09-01","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":1006,"armGroups":[{"label":"IDeg OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin aspart"]},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec","otherNames":[]},{"name":"insulin glargine","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For MAIN period (NN1250-3582):\n* Type 2 diabetes mellitus for at least 6 months\n* Ongoing daily treatment with insulin (premix, self-mix, basal only, basal bolus) for at least 3 months with/without oral anti-diabetics drug (OAD) prior to trial start\n* HbA1c 7.0-10.0 % (both inclusive)\n* Body Mass Index (BMI) below or equal to 40.0 kg/m\\^2\n* For EXTENSION period (NN1250-3667):\n* Completion of the 52 week treatment period in NN1250-3582\n\nExclusion Criteria:\n\n* For MAIN period (NN1250-3582):\n* Treatment with other insulin regimens than premix, self-mix, basal only, basal bolus within 3 months\n* Cardiovascular disease within the last 6 months\n* Uncontrolled treated/untreated severe hypertension\n* Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate contraceptive measures\n* Cancer and medical history of cancer","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment","description":"Change from baseline in HbA1c after 52 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.17","spread":"1.03"},{"groupId":"OG001","value":"-1.29","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 78 Weeks of Treatment","description":"Change from baseline in HbA1c after 78 weeks of treatment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.95","spread":"1.13"},{"groupId":"OG001","value":"-1.15","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 52","description":"Mean of 9-point SMPG at 52 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am and before breakfast.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.3","spread":"1.8"},{"groupId":"OG001","value":"6.9","spread":"1.5"}]}]}]},{"type":"SECONDARY","title":"Extension Trial (Secondary Endpoint): Mean of 9-point Self Measured Plasma Glucose Profile (SMPG) at Week 78","description":"Mean of the SMPG at 78 weeks of treatment. Plasma glucose measured: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner, bedtime, at 4 am, before breakfast.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"1.9"},{"groupId":"OG001","value":"6.8","spread":"1.4"}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1039","spread":null},{"groupId":"OG001","value":"1271","spread":null}]}]}]},{"type":"PRIMARY","title":"Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"176","spread":null}]}]}]},{"type":"PRIMARY","title":"Rate of Treatment Emergent Adverse Events (AEs)","description":"Corresponds to rate of AEs per 100 patient years of exposure. Mild AEs: no or transient symptoms, no interference with subject's daily activities. Moderate AEs: marked symptoms, moderate interference with subject's daily activities. Severe AEs: considerable interference with subject's daily activities, unacceptable. Serious adverse event (SAE): AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"411","spread":null},{"groupId":"OG001","value":"403","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"113","spread":null},{"groupId":"OG001","value":"118","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":null},{"groupId":"OG001","value":"266","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1109","spread":null},{"groupId":"OG001","value":"1363","spread":null}]}]}]},{"type":"SECONDARY","title":"Main Trial (Secondary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes are defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes are defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"139","spread":null},{"groupId":"OG001","value":"184","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":139,"n":753},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Diarrhoea","Cough"]}}}